Stand Up To Cancer - standup2cancer.orgThis is where the end of cancer begins
   Please leave this field empty

SU2C Scientific Research Teams

Share this:

Like this page on Facebook

Jeffrey M. Trent, Ph.D., F.A.C.M.G.

Scientific Research Team:
SU2C-MRA Dream Team: Personalized Medicine for Patients with BRAF Wild-Type (BRAFwt) Cancer

Jeffrey M. Trent, Ph.D., F.A.C.M.G.

Jeffrey M. Trent, Ph.D., F.A.C.M.G., is president and research director of the Translational Genomics Research Institute (TGen).

Trent is a recognized expert in the area of human cancer genetics. He has held numerous faculty appointments including at the University of Arizona, the University of Michigan, Johns Hopkins University and Arizona State University. He is a diplomat of the American College of Medical Genetics, and is a member of the Mayo Clinic Comprehensive Cancer Center. He served on the Board of Directors of the American Association for Cancer Research, and is a member of the American Association for the Advancement of Science, the American Society of Human Genetics and the American Society of Clinical Oncology. Trent is the author of over 300 manuscripts in the medical literature, has received numerous honors and awards, and has served on the editorial boards of over a dozen medical journals.

Trent previously served as director of the Division of Intramural Research of the National Human Genome Research Institute at the National Institutes of Health (NIH). Under his guidance from 1993 to 2002, the division became an internationally recognized research center in the field of human genetics. Following his tenure at the NIH, Trent became the founding president and research director of The Translational Genomics Research Institute (TGen) in Phoenix, Ariz., a position he holds today. In February 2009, he also joined Van Andel Research Institute in Grand Rapids, Michigan.

Launch A Star for someone that you love
There are more than 200 different types of cancer.